24 March 2023
BioVitrina, Russia’s new online resource, is an electronic database on biological samples of patients with oncological diseases. The service was developed at the world-class research center “Digital Biodesign and Personalized Healthcare”, Izvestia reports.
BioVitrina can be used to view and analyze data about tissues, plasma, and blood serum of patients. A personal account is created on the website for each donor of a biological sample, where test findings are stored. The data can be used for the selection of therapy.
According to the creators of the website, the global goal of BioVitrina is to help in the research on the fundamentals of the origin of cancer and the study of antitumor drugs (even in the absence of a suitable trial participant). Research can be made more complicated and/or delayed due to the search for volunteers and medical partners for experiments. BioVitrina will allow researchers to quickly create samples for experiments, and will also offer an impressive set of data.
In 2022, Russia’s Prime Minister Mikhail Mishustin signed a decree stating that pharmaceutical companies can receive a grant for the development of standard samples of vital and essential medicines (VED). The document explains that the creation of the resource will help, in particular, to introduce quality control of VED at all stages of their circulation.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024